|
Fawzy A.M., Rivera-Caravaca J.M., Fauchier L., Lip G.Y.H. Response to letter from Du et al. regarding article ‘Sodium-glucose cotransporter-2 inhibitor use was associated with lower risks of stroke and cardiac arrest but not ventricular arrhythmias?’. Diabetes, Obesity and Metabolism. February 2023. 25:630-633. 10.1111/dom.14913
AÑO: 2023; IF: 5.4
|
|
Rivera-Caravaca JM, Badimon L, Ferreira-Gonzalez I, Gomez-Doblas JJ, Roca-Luque I, Lekuona I, Jimenez-Candil J, Rodriguez-Padial L, Gonzalez-Juanatey C, Calvo-Jambrina R, Facila L, Ruiz-Ortiz M, Anguita M, Marin F. Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. Europace. 2022 Jan 4;24(1):4-11. doi: 10.1093/europace/euab131. PubMed PMID: 34115857.
AÑO: 2022; IF: 6.1
|
|
Perez Cabeza AI, Rivera-Caravaca JM, Roldan-Rabadan I, Garcia Seara J, Bertomeu-Gonzalez V, Leal M, Garcia-Fernandez A, Tercedor Sanchez L, Ayarra M, Ciudad M, Castano S, Maestre A, Anguita M, Garcia Bolao I, Marin F. Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General Registry. Eur J Clin Invest. 2022 Apr;52(4):e13709. doi: 10.1111/eci.13709. Epub 2021 Nov 17. PubMed PMID: 34757635.
AÑO: 2022; IF: 5.5
|
|
Lopez-Galvez R, Marin F, Rivera-Caravaca JM. Predicting heart failure in atrial fibrillation patients: What about using biomarkers? Am Heart J. 2022 Sep;251:32-34. doi: 10.1016/j.ahj.2022.05.007. Epub 2022 May 7. No abstract available. PubMed PMID: 35537504.
AÑO: 2022; IF: 4.8
|
|
Carrión-Martínez A., Buckley B.J.R., Orenes-Piñero E., Marín F., Lip G.Y.H., Rivera-Caravaca J.M. Anthropometric Measures and Risk of Cardiovascular Disease: Is there an Opportunity for Non-Traditional Anthropometric Assessment? A Review. Reviews in Cardiovascular Medicine. December 2022. 23. 10.31083/j.rcm2312414
AÑO: 2022; IF: 2.7
|